Bulletin
Investor Alert

Nuvation Bio Inc.

NYS: NUVB

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 23, 2021, 4:12 p.m.

/zigman2/quotes/220091137/composite

$

8.70

Change

+0.09 +1.05%

Volume

Volume 4,350

Quotes are delayed by 20 min

/zigman2/quotes/220091137/composite

Today's close

$ 8.57

$ 8.61

Change

+0.04 +0.47%

Day low

Day high

$8.43

$8.66

Open

52 week low

52 week high

$8.15

$15.23

Open

Company Description

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the ...

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Valuation

Price to Book Ratio

1.81

Efficiency

Income Per Employee

-506,094.00

Liquidity

Current Ratio

0.45

Quick Ratio

0.45

Cash Ratio

0.32

Profitability

Capital Structure

Officers and Executives

Name Age Officer Since Title
Mr. Daniel G. Welch 62 2020 Chairman
Dr. David T. Hung 62 2018 President, CEO & Director
Ms. Jennifer Fox 48 2020 Chief Financial Officer
Dr. Sergey Yurasov 51 2019 Chief Medical Officer
Dr. Gary Hattersley 53 2019 Chief Scientific Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/13/2021 Ecor1 Capital LLC
Director
3,966   Acquisition at $10.27 per share. 40,730
04/13/2021 Ecor1 Capital LLC
Director
27,534   Acquisition at $10.27 per share. 282,774
04/12/2021 Ecor1 Capital LLC
Director
16,745   Acquisition at $9.49 per share. 158,910
04/12/2021 Ecor1 Capital LLC
Director
116,255   Acquisition at $9.49 per share. 1,103,259
04/09/2021 Ecor1 Capital LLC
Director
37,770   Acquisition at $10.03 per share. 378,833
04/09/2021 Ecor1 Capital LLC
Director
262,230   Acquisition at $10.03 per share. 2,630,166
03/30/2021 Robert B. Bazemore
Director
5,000   Acquisition at $9.98 per share. 49,900
02/10/2021 Omega Fund Management LLC
500,000   Award at $10 per share. 5,000,000
02/10/2021 Omega Fund Management LLC
8,130,097   Derivative/Non-derivative trans. at $0 per share. 0
07/06/2020 EcoR1 Panacea Holdings LLC
Director
390,000   Acquisition at $10 per share. 3,900,000
02/10/2020 William Anthony Vernon
Director
50,000   Award at $10 per share. 500,000
02/10/2020 William Anthony Vernon
Director
254,100   Award at $0 per share. 0
/news/latest/company/us/nuvb

MarketWatch News on NUVB

  1. Nuvation Bio started at outperform with $16 stock price target at BMO Capital

    11:22 a.m. March 8, 2021

    - Tomi Kilgore

  2. Nuvation Bio started at outperform with $20 stock price target at Wedbush

    8:28 a.m. March 8, 2021

    - Tomi Kilgore

/news/nonmarketwatch/company/us/nuvb

Other News on NUVB

  1. Panacea Acquisition II prices $150M SPAC IPO in biotech space

    9:15 a.m. April 7, 2021

    - Seeking Alpha

  2. Nuvation Bio's NUV-422 wins FDA 'Orphan Drug' status

    9:00 a.m. March 11, 2021

    - Seeking Alpha

  3. 10-Q: PANACEA ACQUISITION CORP

    11:08 a.m. Nov. 16, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  4. Investors Pump Billions into Biotech Startups

    10:06 a.m. Oct. 22, 2020

    - The Wall Street Journal Interactive Edition

At a Glance

Nuvation Bio, Inc.

1500 Broadway

Suite 1401

New York, New York 10036

Phone

1 6502453818

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

N/A

Net Income

$-18.22M

Employees

36.00

Link to MarketWatch's Slice.